See more : Value HR Co.,Ltd. (6078.T) Income Statement Analysis – Financial Results
Complete financial analysis of MediWound Ltd. (MDWD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MediWound Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- InterPrivate II Acquisition Corp. (IPVA-WT) Income Statement Analysis – Financial Results
- Ampoc Far-East Co., Ltd. (2493.TW) Income Statement Analysis – Financial Results
- Micron Solutions, Inc. (MICRD) Income Statement Analysis – Financial Results
- OrderYOYO A/S (YOYO.CO) Income Statement Analysis – Financial Results
- BELIMO Holding AG (0QMR.L) Income Statement Analysis – Financial Results
MediWound Ltd. (MDWD)
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.69M | 26.50M | 23.76M | 21.76M | 31.79M | 3.40M | 2.50M | 1.56M | 601.00K | 259.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 15.11M | 13.33M | 14.99M | 14.22M | 11.85M | 2.09M | 1.58M | 2.16M | 2.52M | 2.79M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.58M | 13.17M | 8.77M | 7.55M | 19.94M | 1.31M | 918.00K | -600.00K | -1.92M | -2.53M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 19.15% | 49.69% | 36.91% | 34.67% | 62.73% | 38.61% | 36.78% | -38.51% | -319.13% | -975.29% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.47M | 10.18M | 10.26M | 7.70M | 4.97M | 4.07M | 5.46M | 7.07M | 6.02M | 5.35M | 3.64M | 1.56M | 3.02M |
| General & Administrative | 8.57M | 8.33M | 6.11M | 8.69M | 9.31M | 7.99M | 9.14M | 12.49M | 13.29M | 4.72M | 1.63M | 1.14M | 1.24M |
| Selling & Marketing | 2.80M | 2.04M | 3.39M | 3.23M | 4.06M | 4.19M | 5.36M | 8.40M | 9.28M | 8.83M | 2.26M | 0.00 | 0.00 |
| SG&A | 11.38M | 10.37M | 9.74M | 8.69M | 9.31M | 7.99M | 9.14M | 12.49M | 13.29M | 13.55M | 3.89M | 1.14M | 1.24M |
| Other Expenses | 24.00K | 958.00K | -710.00K | -144.00K | 1.17M | -751.00K | 56.00K | 66.00K | 59.00K | 49.00K | 57.00K | 33.00K | 24.00K |
| Operating Expenses | 18.87M | 21.51M | 19.99M | 16.39M | 15.45M | 5.27M | 14.61M | 19.56M | 19.31M | 18.90M | 7.58M | 2.73M | 4.29M |
| Cost & Expenses | 33.98M | 34.84M | 34.98M | 30.60M | 27.30M | 7.36M | 16.18M | 21.71M | 21.83M | 21.69M | 7.58M | 2.73M | 4.29M |
| Interest Income | 2.34M | 270.00K | 11.00K | 297.00K | 434.00K | 412.00K | 0.00 | 1.27M | 288.00K | 4.67M | 1.00K | 6.00K | 32.00K |
| Interest Expense | 427.00K | 8.92M | 903.00K | 832.00K | 925.00K | 892.00K | 478.00K | 847.00K | 444.00K | 2.11M | 2.44M | 673.00K | 591.00K |
| Depreciation & Amortization | 1.30M | 1.27M | 1.24M | 1.09M | 1.15M | 577.00K | 567.00K | 589.00K | 503.00K | 492.00K | 336.00K | 267.00K | 196.00K |
| EBITDA | -4.89M | -18.09M | -11.22M | -7.75M | 3.42M | -5.09M | -13.12M | -18.30M | -20.72M | -18.33M | -6.50M | 12.25M | -4.10M |
| EBITDA Ratio | -26.19% | -35.22% | -42.01% | -35.61% | 17.75% | -99.47% | -525.64% | -1,255.84% | -3,448.25% | -6,281.85% | 0.00% | 0.00% | 0.00% |
| Operating Income | -15.29M | -8.35M | -11.22M | -8.84M | 4.49M | -3.96M | -13.69M | -20.16M | -21.23M | -21.43M | -7.58M | -2.73M | -4.29M |
| Operating Income Ratio | -81.83% | -31.50% | -47.22% | -40.62% | 14.13% | -116.44% | -548.36% | -1,293.65% | -3,531.95% | -8,272.97% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.76M | -11.18M | -2.30M | -436.00K | -2.43M | -1.71M | -846.00K | 1.27M | -444.00K | 2.55M | -920.00K | 14.72M | -532.00K |
| Income Before Tax | -6.53M | -19.52M | -13.52M | -9.28M | 2.07M | -5.67M | -14.53M | -18.89M | -21.67M | -18.88M | -8.50M | 11.99M | -4.82M |
| Income Before Tax Ratio | -34.95% | -73.68% | -56.91% | -42.62% | 6.50% | -166.57% | -582.25% | -1,212.13% | -3,605.82% | -7,287.64% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 185.00K | 78.00K | 27.00K | 325.00K | -1.65M | -9.69M | 8.46M | -1.27M | 861.00K | -2.55M | 7.77M | -13.67M | 1.88M |
| Net Income | -6.72M | -19.60M | -13.55M | -9.60M | 3.72M | -1.06M | -22.15M | -18.89M | -22.09M | -18.88M | -15.35M | 10.94M | -6.17M |
| Net Income Ratio | -35.94% | -73.97% | -57.03% | -44.12% | 11.70% | -31.08% | -887.38% | -1,212.13% | -3,675.21% | -7,287.64% | 0.00% | 0.00% | 0.00% |
| EPS | -0.75 | -3.93 | -3.48 | -2.47 | 0.96 | -0.27 | -6.64 | -6.05 | -7.13 | -6.65 | -5.28 | 3.76 | -2.12 |
| EPS Diluted | -0.75 | -3.93 | -3.48 | -2.47 | 0.96 | -0.27 | -6.64 | -6.05 | -7.13 | -6.65 | -5.28 | 3.76 | -2.12 |
| Weighted Avg Shares Out | 9.01M | 4.99M | 3.89M | 3.89M | 3.88M | 3.87M | 3.33M | 3.12M | 3.10M | 2.84M | 2.91M | 2.91M | 2.91M |
| Weighted Avg Shares Out (Dil) | 9.01M | 4.99M | 3.89M | 3.89M | 3.88M | 3.87M | 3.33M | 3.12M | 3.10M | 2.84M | 2.91M | 2.91M | 2.91M |
MediWound (MDWD) Reports Q4 Loss, Misses Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of 6.25% and 2.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
MediWound to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022
YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fourth...
MediWound to Present at Upcoming Investor Conferences in February
YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming investor conferences in February. Details...
MediWound's EscharEx Mid-Stage Trial Meets Primary Goal In Venous Leg Ulcers
MediWound Ltd (NASDAQ: MDWD) has posted topline results from its U.S. Phase 2 study of EscharEx for the debridement (removal of dead or infected skin tissue for wound healing) of venous leg ulcers (VLUs). The study randomized 120 patients, of which 119 patients...
MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2021 Results - Earnings Call Transcript
MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2021 Results - Earnings Call Transcript
MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and 13.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview For MediWound
MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on Tuesday, 2021-11-16. Here's what investors need to know before the announcement.
MediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparator Study in the Journal of Wound Care
EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar
MediWound to Present at Upcoming Investor Conferences
YAVNE, Israel, Sept. 03, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management will present at the following investor conferences during...
Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2021 Results - Earnings Call Transcript
Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports